| pubmed-article:11489752 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11489752 | lifeskim:mentions | umls-concept:C0194810 | lld:lifeskim |
| pubmed-article:11489752 | lifeskim:mentions | umls-concept:C0065331 | lld:lifeskim |
| pubmed-article:11489752 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:11489752 | lifeskim:mentions | umls-concept:C1515075 | lld:lifeskim |
| pubmed-article:11489752 | lifeskim:mentions | umls-concept:C0206034 | lld:lifeskim |
| pubmed-article:11489752 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:11489752 | pubmed:dateCreated | 2001-8-7 | lld:pubmed |
| pubmed-article:11489752 | pubmed:abstractText | An inverse association has been observed between dietary intake of lycopene and the risk of prostate cancer. We investigated the effects of lycopene supplementation in patients with prostate cancer. Twenty-six men with newly diagnosed, clinically localized (14 T(1) and 12 T(2)) prostate cancer were randomly assigned to receive 15 mg of lycopene (n = 15) twice daily or no supplementation (n = 11) for 3 weeks before radical prostatectomy. Biomarkers of differentiation and apoptosis were assessed by Western blot analysis on benign and malignant parts of the prostate gland. Prostatectomy specimens were entirely embedded, step-sectioned, and evaluated for pathological stage, Gleason score, volume of cancer, and extent of high-grade prostatic intraepithelial neoplasia. Plasma levels of lycopene, insulin-like growth factor-1 (IGF-1), IGF binding protein-3, and prostate-specific antigen were measured at baseline and after 3 weeks of supplementation or observation. Eleven (73%) subjects in the intervention group and two (18%) subjects in the control group had no involvement of surgical margins and/or extra-prostatic tissues with cancer (P = 0.02). Twelve (84%) subjects in the lycopene group and five (45%) subjects in the control group had tumors <4 ml in size (P = 0.22). Diffuse involvement of the prostate by high-grade prostatic intraepithelial neoplasia was present in 10 (67%) subjects in the intervention group and in 11 (100%) subjects in the control group (P = 0.05). Plasma prostate-specific antigen levels decreased by 18% in the intervention group, whereas they increased by 14% in the control group (P = 0.25). Expression of connexin 43 in cancerous prostate tissue was 0.63 +/- 0.19 absorbance in the lycopene group compared with 0.25 +/- 0.08 in the control group (P = 0.13). Expression of bcl-2 and bax did not differ significantly between the two study groups. IGF-1 levels decreased in both groups (P = 0.0002 and P = 0.0003, respectively). The results suggest that lycopene supplementation may decrease the growth of prostate cancer. However, no firm conclusions can be drawn at this time because of the small sample size. | lld:pubmed |
| pubmed-article:11489752 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11489752 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11489752 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11489752 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11489752 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11489752 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11489752 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11489752 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11489752 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:11489752 | pubmed:issn | 1055-9965 | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:SaksTT | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:BanerjeeMM | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:PontesE JEJ | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:BertramJ SJS | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:CrissmanJ DJD | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:LUY KYK | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:SarkarF HFH | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:WoodD PDPJr | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:PollakM NMN | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:KucukOO | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:KhachikFF | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:DjuricZZ | lld:pubmed |
| pubmed-article:11489752 | pubmed:author | pubmed-author:GrignonDD | lld:pubmed |
| pubmed-article:11489752 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11489752 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:11489752 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11489752 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11489752 | pubmed:pagination | 861-8 | lld:pubmed |
| pubmed-article:11489752 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:meshHeading | pubmed-meshheading:11489752... | lld:pubmed |
| pubmed-article:11489752 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11489752 | pubmed:articleTitle | Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. | lld:pubmed |
| pubmed-article:11489752 | pubmed:affiliation | Division of Hematology and Oncology, Wayne State University, and Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA. kucuko@karmanos.org | lld:pubmed |
| pubmed-article:11489752 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11489752 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11489752 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11489752 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11489752 | lld:pubmed |
